{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"MTD defined as the highest dose at which ≤20% of participants experience dose-limiting toxicity (DLT), to define the recommended phase II dose. DLT were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute version 4.0. An AE was considered a DLT if it occurred in cycle 1, was deemed related to study treatment, and was one of peripheral neuropathy ≥grade 2, any non-hematologic AE ≥ grade 3, neutropenia grade 4 lasting ≥7 days or with fever, thrombocytopenia grade 4 lasting ≥7 days or with bleeding, or any AE requiring a dose reduction during cycle 1 or a delay in the start of cycle 2.","groups":[{"description":"All participants who received at least two cycles of CFZ either at 27mg/m\\^2, 36mg/m\\^2, 45 mg/m\\^2, or 56mg/m\\^2.","id":"OG000","title":"CFZ With Bendamustine and Dexamethasone"}],"paramType":"NUMBER","populationDescription":"A total of 19 out of 19 participants were analyzed when evaluating the maximum tolerated dose. Participants who received dose level 5 continued to be evaluated for dose limiting toxicities.","reportingStatus":"POSTED","timeFrame":"6 months","title":"Maximum Tolerated Dose (MTD) of Carfilzomib in Combination With Bendamustine and Dexamethasone","type":"PRIMARY","unitOfMeasure":"mg/m^2"}